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Introduction 
Ligands that act as antagonists and partial agonists have 
been defined for many receptors. It is, therefore, not unex- 
pected that they can also be generated for the T cell recep- 
tor for antigen (TCR). What is surprising is the similarity 
of these ligands to the normal stimulatory (agonist) ligands 
for the TCR: it is now well established that subtle variants 
of the antigenic peptide-MHC complex, presented by nor- 
mal antigen presenting cells (APCs), can act as specific 
TCR antagonists and partial agonists. Since their initial 
description about 3 years ago, a growing list of effects of 
these ligands on T cell activation and differentiation have 
been described, and recent evidence suggests that similar 
ligands may occur in nature. These facts have generated 
considerable interest in the potential role (either natural 
or therapeutic) of TCR agonists and antagonists in T cell 
ontogeny and regulation of the T cell response. 
Little is known, however, about the mechanism bywhich 
TCR antagonists or partial agonists have their effects. This 
is partly owing to the nature of the TCR ligand, a tight 
physical complex of a peptide antigen bound to a self-MHC 
molecule, which is offered to the T cell on the surface of 
an APC. With such a ligand, it is technically difficult to 
control precisely or to quantitate the concentration of ago- 
nist and antagonist ligands in the local area of T cell-APC 
contact, where the T cell signaling events occur. 
The purpose of this review is to discuss how the exis- 
tence of TCR antagonists and partial agonists can be in- 
corporated into current models of T cell activation, and 
what roles these ligands may play in vivo. 
Agonists, Antagonists, and Partial Agonists 
In classical receptor theory, it was recognized that to pre- 
dict the biological effect of a ligand engaging its receptor, 
one needed to know not only the binding strength of this 
interaction (i.e., the receptor-ligand affinity) but also the 
capacity of the ligand to provoke a biological response 
once it binds that receptor (i.e., the efficacy of the ligand) 
(Stephenson, 1956; Bourne and Roberts, 1987; Kenakin, 
1993). The repercussions of this are illustrated schemati- 
cally in Figure 1. This model shows four ligands that bind 
a cell surface receptor with identical affinity but exhibit 
different degrees of efficacy. Ligand 1 has high efficacy 
and stimulates full activation through the receptor, as read 
out by the cellular responses X and Y. Ligand 2, on the 
other hand, has very low efficacy and does not stimulate 
any of these responses. Owing to its capacity to engage 
the receptor efficiently, however, ligand 2 can block bind- 
ing of ligand 1 and so competitively inhibit ligand 1 from 
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inducing a response. In this way, ligand 2 acts as a revers- 
ible competitive antagonist for the response. (There are 
also irreversible antagonists, which bind with very high 
affinity or covalently to the ligand binding site of the recep- 
tor [Bourne and Roberts, 1987; Kenakin, 19931; this type 
of ligand will not be discussed here). Partial agonistsstimu- 
late either a subset of the typical panoply of responses 
(ligand 3) or induce reduced degrees of maximal re- 
sponse, compared with a full agonist (ligand 4). 
Using strict terminology, the measure of efficacy is de- 
termined for a certain response (or set of responses) via 
a defined receptor on a particular cell type (Kenakin, 1987, 
1989). In this way, agonists for one response may be an- 
tagonists for another, e.g., a ligand may be an agonist for 
muscle contraction and simultaneously an antagonist for 
muscle relaxation. Furthermore, partial agonists can si- 
multaneously exhibit antagonist properties, since they 
may prevent the receptor from binding, and hence re- 
sponding to, a full agonist. Relevant to our discussion be- 
low, the efficacy of a ligand through a receptor can be 
strongly influenced by the nature of the responding cell or 
tissue. A well-known example is the 8-adrenoceptor ligand 
prenalterol, which is a full agonist, a partial agonist, or an 
antagonist for muscle contraction depending on the type 
of tissue examined (Kenakin, 1987). These differences in 
efficacy can be due to receptor density (actually the num- 
ber of “spare” receptors; see below), altered signal trans- 
duction coupling to the receptor, or the influence of core- 
ceptors (Bourne and Roberts, 1987; Kenakin, 1987,1989; 
Hoyer and Boddeke, 1993; Lefkowitz et al., 1993; Schutz 
and Freissmuth, 1992). It is important to realize that, in 
this model, efficacy is not dependent on the degree of 
receptor occupancy: partial agonists and antagonists 
could occupy all the relevant receptors on the surface of 
a cell and still fail to induce “normal” activation. However, 
as we will see below, in the specific case of the TCR, 
receptor occupancy could well contribute to the efficacy 
of a ligand. 
What Determines Efficacy? 
Two general models have emerged to account for the abil- 
ity of a ligand to stimulate a receptor. In the first, an agonist 
ligand induces a conformational change in the receptor, 
which is essential for the intrinsic function of the receptor 
(e.g., in the case of ligand activated ion channels like nico- 
tinic acetylcholine receptor [Pallotta, 19911) or itscapacity 
to couple with signal-transducing molecules (some G pro- 
tein-coupled receptors, like f3-adrenoceptors, seem to be- 
have in this way [Lefkowitz et al., 19931) or both. In the 
second and more recently proposed model, the ligand di- 
rects multimerization or cross-linking of the receptor, 
which allows cross-activation of the signal-transducing 
portions of the receptors (Schlessinger and Ullrich, 1992; 
Ullrich and Schlessinger, 1990; Wells, 1994). This can 
occur with dimeric (e.g., PDGF [Claesson-Welsh, 1994)) 
or divalent ligands (e.g., HGH [Cunningham et al., 1991; 
Wells, 19941). Finally, there are other receptors whose 
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Figure 1. What Are Agonists and Antagonists? 
In this schematic, four ligands (l-4) bind with equal affinity to a cell surface receptor. Upon engagement of the receptor, cellular activation may 
be read out as response X or response Y. The induction of these responses by the various ligands at receptor saturation is shown for each ligand. 
This allows classification of the ligands as agonists, antagonists, and partial agonists. 
activation seems to involve both mechanisms. For exam- 
ple, dimerization of the epidermal growth factor (EGF)R 
is necessary for activation, yet EGF is a monomer. Al- 
though this mechanism is not resolved, it may be that 
EGF binds more strongly to randomly dimerized EGFR, or 
induces a conformational change that favors dimerization 
(for further discussion see Schlessinger and Ullrich, 1992). 
Other receptors exist constitutively as dimers but need a 
conformational change to become activated; insulin re- 
ceptor is a classic example of this (Lee and Pilch, 1994). 
Something goes wrong in these orderly events when 
antagonists or partial agonists bind the receptor. An antag- 
onist may engage a receptor without inducing a conforma- 
tional change, or instead induce a novel conformation that 
favors dissociation of the signal transduction machinery 
(Schutz and Freissmuth, 1992). Alternatively, an antago- 
nist might possess a single receptor binding site, versus 
two binding sites on an agonist (Fuh et al., 1992, 1993): 
receptor affinity for the univalent or divalent ligand may 
not be altered (although, importantly, the avidity of the 
interaction will be altered), so the antagonist can effec- 
tively mop up receptors, thus competitively inhibiting the 
agonist response. Partial agonists are a little harder to ex- 
plain. Here the degree of receptor conformational change 
or multimerization, measured either by the number of Ii- 
ganded receptors that adopt these states or qualitative 
differences in the actual receptor states, presumably de- 
termines the outcome. 
How Receptor Density Modifies Efficacy: 
Spare Receptors 
As mentioned above, other factors that influence efficacy 
include receptor density. This conclusion arises from con- 
sidering spare receptors. If it is the case that not all the 
receptors on a cell need to engage a full agonist to induce 
full activation, there are said to be spare receptors or a 
“receptor reserve” (Black and Leff, 1983; Bourne and Rob- 
erts, 1987). With high numbers of spare receptors for the 
full agonist, antagonism will be hard to demonstrate. This 
is because the antagonist must occupy nearly all the cell 
surface receptors before affecting stimulation by the ago- 
nist. ‘Weaker” agonists (lower in either efficacy or affinity 
for the receptor) might be able to act as full agonists in 
this case, but would require all the available receptors to 
do so (i.e., for these weaker ligands, there are no spare 
receptors). If there are no spare receptors for the full ago- 
nist, an antagonist will be very potent, and the weaker 
ligand can now only act as a partial agonist (of type 4) or 
even an antagonist. To finish the progression, reduction 
of the receptor density further will mean there can be no 
full agonists, only partial agonists. These descriptions as- 
sume an excess of free ligand; if ligand is also limiting 
then the predicted reactivity gets even more complicated. 
Clearly, then, it is unwise to think of a ligand as being 
an agonist or antagonist for a receptor without considering 
the receptor-ligand abundance and the number of spare 
receptors. 
Efficacy for the TCR 
As described above, understanding the efficacy of a ligand 
depends on understanding what is involved in receptor 
activation. What does it take to activate a TCR? 
The TCR typically recognizes a ligand consisting of two 
components: an MHC molecule and a short (8-l 4 aa) pep- 
tide bound to that MHC molecule. Although the relative 
contribution of the interaction of the TCR with MHC versus 
peptide residues is not well defined, and is probably differ- 
ent for different TCRs, it is clear that both components 
influence TCR association. Thus, alterations of the resi- 
dues that project toward the TCR in either the bound pep- 
tide or the MHC molecule can dramatically affect TCR 
recognition. 
Probably the first step in stimulation through the TCR 
is activation of various tyrosine kinases. Some of these 
kinases (including Fyn, ZAP-70, and perhaps Syk) become 
associated with the TCR complex components CD3 and 
r;, while another kinase, Lck, is brought into the interaction 
site by virtue of its association with the coreceptors CD4 
and CD8 (Perlmutter et al., 1993; Chan et al., 1994). It 
seemsthatcooperation of kinasesfrom thesrcfamily(Fyn, 
Lck) and Syk family (ZAP-70 and possibly Syk itself) is 
required for full TCR-induced activation (Iwashima et al., 
1994; Kolanus et al., 1993). The tyrosine phosphatase 
CD45 is also needed for efficient TCR signaling, and some- 
where in this milieu the Ras activation pathway is also 
induced (Perlmutter et al., 1993; Chan et al., 1994). 
How does the TCR-ligand interaction direct these 
events and, pivotal for this discussion, what happens when 
it goes wrong? The popular model is that the TCR requires 
cross-linking to undergo activation. TCR aggregation, es- 
pecially with coaggregation of the coreceptor molecules 
on the T cell surface, could focus the kinases in one place, 
allowing amplification of a rare signal, or inducing new 
signals when kinases that rarely meet are drawn together. 
On the other hand, ligand binding to the TCR could pro- 
mote a conformational change in the receptor and directly 
activate the bound kinases, encourage kinase docking, 
or permit an association with other cell surface receptors, 
e.g., the coreceptors. Again, these models of activation 
are not mutually exclusive. The events may occur sequen- 
tially; for example, a conformational change being the nat- 
ural way to induce TCR cross-linking. Alternatively, both 
pathways could operate under different conditions, or in 
T cells at different stages of maturation. We will return to 
these issues again later. 
In addition to the TCR itself, other receptors contribute 
to T cell activation. The coreceptor molecules CD4 and 
CD8 also bind MHC molecules, on a nonpolymorphic site 
distinct from that recognized by the TCR, and contribute 
to both cell-cell adhesion and T cell signaling. Further- 
more, a plethora of adhesion and costimulator molecules 
contribute to interactions between the T cell and APC, 
augmenting or altering T cell activation. The complex na- 
ture of the TCR-APC interaction makes analysis of the 
TCR signaling mechanism difficult. 
T Cell Receptor Antagonists and Partial Agonists 
That TCR antagonists would exist was predicted several 
years ago (Mannie, 1991) but has received experimental 
support only recently. Identification of these ligands and 
TCR partial agonists came chiefly from analysis of variants 
in the peptide component of the ligand of the TCR. Amino 
acid substitutions at predicted TCR contact sites in an 
antigenic peptide can alter the interaction of the peptide 
with the TCR, without affecting peptide association with 
the relevant MHC molecule. Some variants of the antigen, 
when presented as a peptide-MHC complex, appear to 
act as competitive partial agonists and antagonists. It 
should be stressed that the action of these altered peptides 
requires their presentation by appropriate MHC mole- 
cules; thus, the short-hand nomenclature of, for example, 
TCR antagonist peptides, although convenient, is mis- 
leading. 
Partial Agonists 
Originally demonstrated by Evavold and Allen (1991) a 
number of reports have now appeared describing uncou- 
pling of different T cell responses by certain TCR ligands 
(for recent reviews see Evavold et al., 1993b; Sette et 
al., 1994). For example, the wild-type TCR ligand may 
stimulate helper T cell proliferation, cytokine secretion, 
and cytotoxicity over a similar dose range, but variants of 
this peptide may induce cytokine production or target cell 
lysis in the absence of T cell proliferation (Evavold and 
Allen, 1991; Evavold et al., 1993a). These ligands have 
the properties of partial agonists (of either type 3 or 4 in 
Figure 1). As such, they can also act as competitive antag- 
onists for T cell responses. 
TCR Partial Agonists and Anergy 
The phenomenon of differential signaling has some inter- 
esting similarities with anergy. In the two-signal model of 
T cell activation, engagement of both the TCR (signal 1) 
and costimulator receptors (signal 2) is required for full 
T cell stimulation. When the TCR signal is delivered in 
isolation, a partial form of T cell activation results, leaving 
the T cells in a temporary refractory state (i.e., anergized), 
unable to respond fully to antigen even when presented 
in the context of signal 2 (Mueller et al., 1989; Schwartz, 
1990). In the best-analyzed system of anergy, that of 
mouse Thl cells, signal 2 is apparently mediated by en- 
gagement to the B7 family of costimulator molecules 
(Schwartz, 1990; Juneet al., 1994). The respondingTcells 
make some early responses but later events, especially 
IL-2 synthesis and proliferation, are completely blocked. 
Similar findings have now been observed using peptide 
variants of the antigen. Certain TCR partial agonists in- 
duce early events but fail to activate proliferation and pro- 
duction of some cytokines (Evavold and Allen, 1991; Raci- 
oppi et al., 1993; Sloan-Lancaster et al., 1993, 1994a; 
Page et al., 1994). Some of these peptide-MHC variants 
can induce anergy in both Thl (Sloan-Lancaster et al., 
1993) and Th2 (Sloan-Lancaster et al., 1994a) clones, de- 
spite the expression of functional costimulator molecules 
on the APCs involved. It is not clear, however, whether 
this is a general rule for all TCR partial agonists, and 
whether TCR antagonists also induce anergy. 
TCR Antagonists 
Pure antagonists are nonstimulatory ligands identified by 
their capacity to compete with agonists for receptor occu- 
pancy. The experimental methodology for unambiguously 
demonstrating TCR antagonism is complicated for two 
reasons. First, the peptide-MHC ligand is typically ex- 
pressed on the cell surface, which severely limits the ca- 
pacity to mix two different ligands in a controlled way. 
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Second, the ligand is itself composed of two parts; thus, 
binding of the antigenic peptide to the MHC molecule must 
precede interaction of this complex with the TCR. The 
practical impact of this is that inhibition of either binding 
step will result in a block in T cell stimulation. Thus, in 
experiments using peptide variants there is the risk of 
MHC blockade masquerading as TCR antagonism. 
The first description of TCR antagonism avoided most 
of these technical limitations by examining T cells with 
the unusual property of responding to a hapten. Rao and 
colleagues (Rao et al., 1984a, 1984b) showed that reactiv- 
ity of T cells specific for arsonate-conjugated proteins 
could be inhibited by derivatized variants of arsonate, 
which bind the TCR but are poor stimulators of activation. 
In this way, the variant arsonate antagonized the T cell 
response toward unmodified arsonate. In elegant experi- 
ments using T cell hybridomas reactive with fluorescein, 
Dintzis and colleagues (Symer et al., 1992) showed that 
decreasing the density of fluorescein moieties arrayed on 
a polymer backbone can convert the activity of the ligand 
from that of a TCR agonist to that of an antagonist. Their 
conclusion was that a dense physical array of TCR ligands 
allows formation of a patch or cluster of TCRs, which would 
be sufficient for activation. Lowering of the ligand density 
has the effect of engaging the TCR without allowing clus- 
tering, and therefore acting as a competitive antagonist 
for activation (Symer et al., 1992). Although the data are 
persuasive, these systems have the limitation that they 
involve an aberrant T cell reactivity: hapten binds directly 
to these TCRs, and activation of these T cells appears not 
to require normal MHC and coreceptor interactions (Rao 
et al., 1984a, 1984b; Symer et al., 1992; Diamond et al., 
1991). These issues raise the concern that these models 
do not reflect typical activation through the TCR. 
Studying Tcell responses involving MHC-restricted pep- 
tide antigens has necessitated avoidance of MHC block- 
ade. Typically, APCs are pulsed first with a dose of the 
antigenic peptide, which will occupy only a fraction of the 
available MHC sites but will produce T cell stimulation. 
Unbound peptide is washed away, the candidate variant 
peptide is pulsed onto the APCs, and the T cell response 
then assessed. Sequential binding thus eliminates the ef- 
fect of MHC binding competition between the peptides. 
However, this method is not entirely satisfactory, as it is 
possible that the second peptide may in some way dis- 
place the first (agonist) peptide, decreasing its MHC occu- 
pancy at a later stage. When and how displacement occurs 
is still controversial (e.g., see de Kroon and McConnell, 
1994) but this is even more reason to exclude it as a 
possible artifact in antagonism assays. There is clear evi- 
dence against displacement as an alternative explanation 
for the observed inhibition. Addition of variant peptides 
does not noticeably alter the dissociation rate of the anti- 
genie peptide (De Magistris et al., 1992). The inhibitory 
effects of variant ligands are often T cell clone specific, 
not correlating to sensitivity of the T cells. Thus, if one 
considers two T cell clones, A and B, which recognize 
the same antigen-MHC but use different TCRs, variant 
peptide l/MHC may antagonize the response of A but not 
B, whereas variant 2lMHC antagonizes the response of 
clone B but not A (Jameson et al., 1993). Peptide displace- 
ment would not predict this “flip-flop” pattern of inhibition. 
In some instances, it has been possible to analyze systems 
in which MHC binding competition is not an issue: Evavold 
et al. (1994) used bacterial superantigen-MHC as an ago- 
nist and peptide-MHC as an antagonist. Since super- 
antigens and peptides do not compete for MHC class II 
molecule binding, these observations argue against com- 
petition or displacement as a model. In some experiments, 
T cells have been used that respond through two distinct 
MHC molecules; the response to one can be antagonized 
with peptides binding to the other (Racioppi et al., 1993). 
Are these ligands really strict antagonists or are they 
partial agonists? This question is difficult to answer defini- 
tively for any antagonist. For example, in Figure 1, our 
antagonist ligand 2 may actually be a partial agonist, owing 
to its capacity to stimulate a newly discovered cellular re- 
sponse, Z. Some TCR antagonist ligands seem incapable 
of stimulating T cell responses, ranging from rapid events 
such as calcium flux and phosphatidyl inositol turnover 
through to later events such as cytolysis, lymphokine se- 
cretion, and proliferation (De Magistris et al., 1992; Rup- 
pert et al., 1993; Jameson et al., 1993). However, with 
increasing sensitivity and refinement of assays for T cell 
activation, responses may be found that are directly stimu- 
lated by TCR antagonists. In particular, it is not clear 
whether TCR antagonists are capable of stimulating the 
most rapid activation events, such as tyrosine kinase acti- 
vation. This is especially relevant since recent evidence 
has suggested that altered tyrosine phosphorylation may 
correlate with some forms of partial agonism (Sloan- 
Lancaster et al., 1994b). Furthermore, there is evidence 
that certain peptide-MHC ligands can act as strict antago- 
nists for mature T cells, but drive differentiation of imma- 
ture thymocytes (discussed further below). This could be 
regarded as a form of partial agonism. Clearly, further 
analysis will be required to ascertain whether all TCR an- 
tagonists are, in fact, partial agonists of some sort. 
Models for TCR Partial Agonism and Antagonism 
We can exclude some models from consideration fairly 
quickly. One is total receptor occupation. TCRs are ex- 
pressed at tens of thousands of copies on a T cell surface; 
the number of agonist or antagonist peptide-MHC com- 
plexes that are achieved by peptide loading of MHC mole- 
cules on the APC surface is typically in the order of a 
hundred, and at maximum, maybe a thousand molecules. 
Thus, there is no way to account for antagonism by mop- 
ping up of all the TCRs on the T cell (see Janeway, 1993; 
Sette et al., 1994). Note, however, that this argument does 
not rule out the possibility that TCR antagonists may act by 
nonproductive engagement of a critical number of TCRs 
locally, i.e., in a small defined patch of the T cell mem- 
brane. This scenario will be examined in more detail below. 
A second model that fails to account for the data is to 
assume simple thresholds for activation that create a hier- 
archy of responses dependent on dose. For example, 
some responses might always be easier to trigger than 
others. This prediction doesn’t appear to hold true, since 
the majority of data describes multiple T cell effector func- 
CD8a@ Figure 2. Individual Receptor Model 
Ligand engagement may activate individual 
TCRs. This could involve a conformational 
change and/or the local participation of core- 
ceptors (CD8 in this case of a class I MHC- 
restricted T cell) and costimulator receptors. 
These events occur with an agonist but not with 
an antagonist. Partial agonists may induce the 
correct (activating) conformation only infre- 
quently (not shown). 
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tions induced by antigen-MHC with essentially overlap- 
ping dose response curves. The existence of partial ago- 
nists of the type described by Evavold and Allen indicates 
instead that some ligands, but not others, are capable of 
uncoupling T cell responses. 
The data, then, suggest a qualitative difference between 
the way in which the TCR transduces signals from each 
type of separable response (for instance, the way in which 
triggering through the TCR for proliferation is different 
from that for lymphokine secretion). 
But at what stage of TCR interaction or signaling do 
these pathways diverge? This again returns to the issue 
of how T cell activation is mediated in the normal situation, 
i.e., by an agonist. The pivotal question is what is the criti- 
cal event that initiates the signaling cascade. It may be that 
the basic unit of T cell activation is a single TCR (Figure 2). 
When this receptor binds an agonist ligand it might induce 
a conformational change, activating the receptor, possibly 
by favoring an interaction with the coreceptors or costimu- 
lator receptors. From another angle, engagement of a sin- 
gle TCR might be sufficient to induce local binding of the 
coreceptor, without the need to invoke a conformational 
change. An alternative model is that the binding of a single 
TCR is entirely without consequence. In this scheme, it 
is only when the TCR is multimerized that it can begin to 
participate in the signaling cascade (Figure 3). Again, CD4 
and CD8 and the costimulators may play a crucial role in 
forming this cross-linked patch or in modulating the signals 
that will ensue. 
Starting with these two broad models, there are various 
ways in which antagonists and partial agonists could inter- 
fere with the normal signaling events. Their effects could 
be mediated at the level of TCR conformational changes; 
alterations in the size or speed of TCR clustering; changes 
in the coordination of TCR clustering with the participation 
of other receptor molecules, such as coreceptors; or, fi- 
nally, induction of an atypical signaling pathway that medi- 
ates a negative signal. Let us consider these possibilities 
in turn. 
TCR Conformational Changes 
A qualitative difference in the way the TCR actually inter- 
acts with various ligands may be at the root of differential 
signaling. Conformational changes in the TCR could pro- 
vide a mechanism for this. 
Different TCR conformations could alter the signal trans- 
duction pathway(s) employed through the TCR by chang- 
ing the relative position or accessibility of tyrosine kinases 
(e.g., Ick, ZAP-70, fyn), tyrosine phosphatases (e.g., 
CD45), and/or the substrates of these enzymes. The at- 
traction of this model versus others is that each TCR acts 
independently. It is easy to see then how an abundance 
of ligands that fail to provoke a conformational change, 
i.e., an antagonist, would compete with an agonist ligand. 
A partial agonist might only induce the change in a subset 
of bound TCRs or fail to drive the complete altered state, 
and so alter the range of signal transduction molecules 
associated to the TCR complex. 
Another mechanism, in line with stimulation through 
some growth factor receptors, is that the conformational 
change may itself induce TCR cross-linking (Schlessinger 
and Ullrich, 1992). Thus, both events would be required 
for full agonism of the TCR. Cross-linking in the absence 
of conformational change (or vice versa) might lead to no 
activation, or some partial activation. 
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Figure 3. Cross-Linked Receptor Model 
The first event in activation of TCRs may be their aggregation. Agonists 
achieve this efficiently (perhaps with the assistance of coreceptors), 
whereas antagonists are poor at inducing cross-linking. This may be 
due to slower kinetics of receptor-ligand binding (or faster dissocia- 
tion) and/or could reflect lessened recruitment of the costimulator mol- 
ecule receptors (data not shown) and coreceptors (e.g., CD8). When 
both ligands are present on the same cell, the receptors engage in 
unstable complexes with the antagonists (in excess), and this prevents 
formation of a stable cross-linked patch with theagonist. Symbols are 
as in Figure 2. 
The downside of these models is that there is scant 
data for or against a TCR conformational change during 
activation, whereas there is abundant evidence that unnat- 
ural TCR cross-linking, e.g., using monoclonal antibodies, 
can stimulate activation. On the other hand, it is not clear 
that stimulatory antibodies act solely by cross-linking the 
receptor. It is known that binding of certain antibodies can 
induce an activated conformation of a receptor; for exam- 
ple, this has been demonstrated using the insulin receptor 
(Lebrun et al., 1993). Antibodies to the TCR might act in 
the same way. Indeed, the Janeway group has described 
anti-TCR antibodies that appear to differ in their capacity 
to induce activation, irrespective of their affinity for the 
TCR (Janeway et al., 1989; Rojo and Janeway, 1988). 
Furthermore, recent data from that group suggests that 
certain anti-TCR antibodies can act as competitive antago- 
nists (Yoon et al., 1994), suggesting that the role of confor- 
mational changes in TCR activation should be reexamined. 
TCR Cross-Linking 
If TCR ligands differ in their capacity to promote TCR 
cross-linking, this could change how large a cross-linked 
patch is generated, how quickly it forms, or both. These 
parameters might affect full signaling by changing the 
magnitude, timing, or order in which early activation 
events occur. For example, TCR dimerformation may initi- 
ate some early signaling events but fail to feed into the 
amplifying cascade of signals that would occur when a 
larger array of bound TCRs is generated. One could also 
imagine that the result of signaling from small oligomeric 
clusters might also preempt the signal pathway for larger 
clusters. For example, initiating regulatory pathways for 
dampening down the response before it had progressed 
sufficiently, thus producing the effect of antagonism. 
In another version of this model, the role of coreceptors 
could be critical. For example, TCR binding to an agonist 
seems to potentiate coreceptor molecule binding (Sai- 
zawa et al., 1987; Rojo et al., 1989; O’Rourke et al., 1990; 
O’Rourke and Mescher, 1992; Yoon et al., 1994), involving 
some rapid signaling event(s) (O’Rourke and Mescher, 
1992, 1994). If an interaction with an antagonist (or partial 
agonist) failed or delayed the induction of coreceptor bind- 
ing, this could deprive the TCR cross-linked patch of Ick, 
which is strongly implicated in the normal activation path- 
way. In this way, the actual composition of the signaling 
complex could be changed. 
In what way could different ligands alter the size or rate 
of clustering? One model proposed by several groups is 
that antagonists may have a lower affinity for the TCR than 
agonists (for earlier reviews see Evavold et al., 1993b; 
Sette et al., 1994). In this scheme, the TCR interacts 
weakly with the antagonist ligand, never achieving suffi- 
cient density of engaged receptors to start signaling. A 
partial agonist could be similar, but would induce some 
limited signaling by being of slightly higher affinity. 
In support of the notion that at least some antagonists 
provide low affinity ligands for the TCR is the fact that 
antagonist variants of the antigenic peptide are relatively 
easy to find. For example, Alexander et al. (1993) analyzed 
variants at five TCR contact sites of a HLA-DRl-restricted 
influenza HA peptide; around 75% of single amino acid 
variants acted as TCR antagonists for a single clone. Simi- 
larly, Jameson et al. (1993) showed that 24 of 48 (- 50%) 
single amino acid variants at three TCR contact sites of 
a H-2Kb-restricted OVA peptide acted as TCR antagonists 
for a panel of T cell clones. Furthermore, in both studies 
substitution at certain key peptide residues frequently 
yielded antagonists (75%-100% of substitutions tested). 
These substitutions include radical changes in the TCR 
contact residues, some of which at least are likely to re- 
duce the affinity for the TCR. 
One prediction of this model is that it should be possible 
to convert an antagonist into an agonist by simply raising 
its concentration. These ligands would thus be types of 
agonist/antagonists (see Kenakin, 1987). Although this 
sometimes happens (Jameson et al., 1993; Hogquist et 
al., 1994b; Alexander et al., 1993) it is not evident in every 
case. It has also been argued that the affinity model cannot 
explain antagonism because it requires an antagonist li- 
gand to soak up all the available TCRs on the surface of 
the T cell, which is untenable, because of the excess of 
TCRs relative to specific peptide-MHC molecules, as dis- 
cussed above (Janeway, 1993). Both of these arguments 
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make the implicit assumption that essentially all the MHC 
ligands are available to all the TCRs and binding of the 
receptor to ligands on any part of the cell will suffice for 
activation. If, instead, thesiteof interaction between these, 
the receptor-bearing T cell and ligand-bearing APC, is a 
small patch of membrane contact, then the rules change. 
Under these conditions, T cell activation results from a 
critical number of TCRs (let’s say 4) simultaneously bind- 
ing a peptide-MHC ligand in a small area of membrane. 
Binding of TCRs to a ligand that disassociates before the 
fourth receptor comes to rest in that defined patch will 
spoil aggregate formation. Since TCRs would be occupied 
by these “unstable” ligands, stimulation via the wild-type 
antigen would be inhibited (i.e., antagonized). Similar 
patches could begin to form all over the cell, but share a 
similar fate. Hence, the ratio of agonist to antagonist Ii- 
gands will determine outcome rather than their absolute 
number. 
Ironically, it is the pure conformational change model 
for agonism that suffers from considering the number of 
TCRs and specific MHC ligands on cells. If a conforma- 
tional change by a single TCR rather than patch formation 
is required for activation, it should be possible for the over- 
abundance of TCRs to find agonists, even in the presence 
of proportionately high numbers of antagonist ligands. 
The Contribution of Other Receptors 
Expressed on T Cells 
Most experiments on TCR agonism and antagonism have 
involved MHC-associated antigens expressed on conven- 
tional APCs. As a consequence of this, at least three other 
classes of T cell receptors become involved: coreceptors 
(CD4, CD8), costimulator ligands (e.g., CD28, CTLA4) 
and adhesion molecules (e.g., LFA-1, ICAM-1). There 
have been some efforts to see what effect these interac- 
tions play in TCR agonism and antagonism. It appears 
that coreceptor expression can influence the apparent effi- 
cacy of a TCR ligand. Decreasing cell surface CD8 expres- 
sion levels on an MHC class l-restricted CTL converts an 
agonist ligand into an antagonist (Jameson et al., 1994). 
Similar conclusions have recently been made by studying 
the CD4 dependence of MHC class II-restricted helper T 
cells (P. Allen, personal communication). These data are 
most easily incorporated into the cross-linking model de- 
scribed above. Increasing coreceptor expression levels 
may facilitate simultaneous engagement of the TCR and 
CD4 or CD8 with the same peptide-MHC complex. Such 
a change may increase the avidity andlor efficiency of 
signal transduction through the TCR when it binds to a 
ligand with low affinity or a fast on/off rate. One obvious 
question is whether the coreceptor needs to be competent 
for inducing signal transduction to have this effect; if not, 
this implies that merely changing the avidity of the interac- 
tion of the T cell can affect efficacy. Experiments are in 
progress to assess this issue. 
The contribution of costimulator and adhesion molecule 
interactions to TCR antagonism and partial agonism is 
unclear. Conflicting results have been observed with re- 
gard to whether IL-2 production by T cell hybridomas (a 
response that appears not to require a costimulator inter- 
action) is susceptible to antagonism (Evavold et al., 1994; 
Racioppi et al., 1993). If antagonists or partial agonists do 
operate through deprivation of costimulation, this process 
does not seem to involve CD28, since activation of CD28 
by antibody cross-linkage does not reverse the inhibitory 
effects (Racioppi et al., 1993; Sloan-Lancaster et al., 1993; 
Evavold et al., 1994). The influence of adhesion molecules 
has not been addressed. 
Negative Signals 
Within the models discussed above, it is assumed that 
partial agonists and antagonists lack the capacity to initi- 
ate full (or any) activation via the TCR, and mediate any 
inhibitory effects by competition with agonists for receptor 
occupancy. A different model is that inhibitory ligands ac- 
tually induce a distinct response through the receptor, 
which acts as a negative signal. In the initial reports there 
was little evidence for this; TCR antagonists appeared to 
inhibit activation only when in high molar excess over the 
agonist (minimally lo- to lOO-fold excess). However, there 
are new data that are hard to reconcile with simple compe- 
tition for receptor occupancy. Antagonists have been de- 
scribed that appear to inhibit activation at molar equiva- 
lence or even lOOO-fold inferiority compared with the 
agonist. These experiments concerned CD8 T cell re- 
sponses to epitopes derived from HIV (Klenerman et al., 
1994) and hepatitis Bvirus(Bertoletti et al., 1994) proteins. 
Addition of low concentrations (10-l’ to 1 Oe8 M) of variant 
peptides could inhibit the T cell response to cells pulsed 
with considerably higher concentrations (1 Om8 to lO-‘j M) 
of the agonist peptide. Some element of this effect may be 
due to different rates of spontaneous peptide dissociation 
from the presenting MHC molecule for the agonist versus 
antagonist complexes (see Bertoletti et al., 1994). How- 
ever, there is also some evidence indicating that antago- 
nist ligands expressed on one APC can inhibit the T cell 
response to an agonist expressed on another cell (Jame- 
son et al., 1993; Klenerman et al., 1994; Bertoletti et al., 
1994). These data do not fit easily into the conformational 
change model and are even harder to incorporate into the 
cross-linking model. Intriguing data from Sloan-Lancaster 
et al. (1994b) demonstrate that some partial agonists in- 
duce incomplete phosphorylation of the TCR 1; chain. This 
type of stimulation might commit the cell to a certain signal- 
ing pathway, blocking its capacity to participate in full TCR 
signaling. 
Testing the Models 
None of the models described above have been thor- 
oughly excluded or included to explain all instances of 
TCR partial agonism or antagonism. Although it would be 
pleasing to hack away at the list with Occam’s razor, we 
are left with the conclusion that different TCR ligands may 
affect T cell activation through distinct mechanisms. 
The more that is known about the TCR interaction with 
agonists, partial agonists, and antagonists, the more eas- 
ily we should be able to rule one model in or out. For 
instance, measurements of the TCR affinity and on/off 
rates for agonists and antagonists is under way in a num- 
ber of labs. If TCR affinity consistently correlates with effi- 
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cacy, this lends some support to the cross-linking or avidity 
models. On the other hand, a total lack of correlation would 
support the conformational change or negative signal 
models. 
The Natural and Therapeutic Roles of TCR Partial 
Agonists and Antagonists 
The properties of partial agonists and antagonists make 
them interesting candidates for exploiting or explaining 
various aspects of T cell activity and development. Thus, 
these ligands may provide a means specifically to control 
or to modify unwanted immune responses, e.g., autoim- 
mune or immunopathological responses. On the other 
hand, TCR antagonism could be exploited by pathogens 
as a method of evading or misdirecting the immune sys- 
tem. Finally, there is accumulating evidence that TCR an- 
tagonists can dramatically influence thymocyte develop- 
ment. These and more speculative ideas about the 
possible roles of TCR antagonists and partial agonists will 
be considered below. 
Specific Blockers of Autoimmune Disease 
TCR antagonists and partial agonists allow blocking or 
redirecting of specific T cell responses despite the con- 
tinued presence of stimulatory complexes on suitable 
APCs. Such ligands could offera highly specific and potent 
treatment to inhibit or modulate a pathological T cell re- 
sponse. These optimistic expectations must be tempered 
by two hard facts. First, most TCR partial agonists and 
antagonists described to date are highly T cell clone spe- 
cific. Thus, a ligand that acts as an antagonist of one T 
cell may be a null ligand (i.e., ignored) or, much worse, an 
agonist for another clone of the same antigen specificity. 
Hence, using peptide variants to antagonize one set of T 
cells could actually augment another set reactive for the 
same antigen. The second problem is that before variant 
ligands can be generated, the antigenic ligand itself must 
first be identified, something that is still lacking in many 
human autoimmune diseases. 
Despite these gloomy caveats, there may be some hope 
for this approach. The capacity of single variant peptide- 
MHC ligands to act as TCR antagonists of polyclonal T 
cells using an invariant TCR 8 chain but distinct a chains 
has been described (Dillon et al., 1994; P. Allen, personal 
communication). Since some autoimmune diseases in- 
volve T cells with fairly restricted TCR usage, it may be 
possible to design more reliable low efficacy ligands. Fur- 
thermore, recent experiments have shown that experi- 
mental allergic encephalomyelitis can be inhibited by 
cocktails of myelin proteolipid protein variant peptides 
(Kuchroo et al., 1994). Each of these variants (when pre- 
sented by appropriate MHC) antagonizes only a proportion 
of proteolipid protein reactive clones (the best result is 
inhibition of about 80% of clones) (Franc0 et al., 1994; 
Kuchroo et al., 1994). However, none were agonists for 
the clones tested. Injection of these peptides inhibited, or 
delayed, or both the onset of experimental allergic enceph- 
alomyelitis. How generalizable these results will prove to 
be is hard to predict. The second problem, that of autoim- 
mune epitope identification, will likely remain. An alterna- 
tive strategy has been proposed using partial agonists. 
Some human MBP-specific Th2 clones, when confronted 
by altered peptide-MHC ligands, are antagonized for IL-4 
secretion and instead secrete TGFp (D. Hafler and A. 
Sette, personal communications). Since the latter cytokine 
can inhibit production of the former, this switch could in- 
hibit the normal Th2 response. Thus, if such a partial ago- 
nist ligand can be presented to T cells at the site of a 
tissue-specific autoimmune reaction, this nonspecific inhi- 
bition by altered cytokine production might inhibit the local 
(but not systemic) immune response. It is early days for 
evaluating such experiments, but these data indicate the 
potential value of TCR antagonists and partial agonists in 
fine tuning the immune response. 
TCR Decoys for Pathogens 
Two reports have indicated that some viruses may utilize 
TCR antagonism to evade a cytotoxic T cell response 
(Klenerman et al., 1994; Bertoletti et al., 1994). In both 
cases, naturally occurring variants in viral epitopes were 
identified. Some of the variants were altered in TCR con- 
tact residues and, when appropriately presented, behaved 
as surprisingly potent TCR antagonists for T cells isolated 
from infected patients. The authors hypothesized that 
such variants could inhibit the response to viruses bearing 
the wild-type epitope, and so prevent immune lysis of host 
cells infected by mixed viruses, some of which do and 
do not have the antagonist mutation. Obviously there are 
other, more selfish, ways for pathogens to evade the CTL 
response (e.g., mutating the epitope at MHC contact sites, 
or completely disrupting TCR binding). However, the an- 
tagonism method may be valuable for two reasons: it might 
allow rare mutant viruses to survive and expand in host 
cells that are simultaneously presenting the wild-type epi- 
tope (because the mutation could dominantly inhibit T cell 
responses); multiple epitope variants could be tested by 
the viruses infecting a single cell, hoping to reach a combi- 
nation that would antagonize all the dominant reactive T 
cell clones. Further analysis will be required to test 
whether this mode of CTL escape is coincidental with, or 
causative of, viral persistence. 
Inducers of Thymocyte Positive Selection 
During T cell development, immature CD4’CD8+ double- 
positive (DP) thymocytes have three possible fates (Robey 
and Fowlkes, 1994). Tosurvive, they must interact in some 
ill-defined way with self-MHC molecules; when they do this 
they mature through the process called positive selection, 
becoming either CD4+CD8- or CD4CD8+ dependent on 
the MHC class recognized by their TCR. On the other 
hand, if the interaction with self-MHC (plus self-peptides) 
is too strong, they will die as DPs by negative selection 
(tolerance). If their TCR is incapable of mediating either 
event, DPs die by default within a few days. 
Little is known about the relationship between peptide- 
MHC complexes that induce positive versus negative se- 
lection; however, interesting candidates seem to be TCR 
antagonists and agonists, respectively (Mannie, 1991; 
Hogquist et al., 1994a; Bevan et al., 1994). Indeed, the 
capacity of TCR antagonists to induce positive selection 
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of CD8’ T cells has now been demonstrated using a TCR 
transgenic model (Hogquist et al., 1994b; Jameson et al., 
1994). These experiments have revealed a remarkably 
good correlation between ligands that act as TCR antago- 
nists for mature CTL and those that induce positive selec- 
tion, indicating that the two phenomena may be related. 
On the other hand, analysis of TCR antagonists in CD4’ 
T cell development appears quite different, at least at first. 
Some antagonists appear to inhibit positive selection 
rather than promote it (Spain et al., 1994). Other antago- 
nists (actually partial agonists) cause negative selection 
(Page et al., 1994). Indeed, no one so far has reported 
induction of CD4+ T cell positive selection using TCR an- 
tagonists. Some of this data can be explained by the type 
of assay employed. For example, deletion of CD4+CD8+ 
thymocytes by antagonists can occur in thymocyte sus- 
pension cultures (Page et al., 1994; Barnden et al., 1994), 
but the same TCR ligands do not induce DP deletion when 
introduced to thymocytes developing in fetal thymic organ 
culture (Hogquist et al., 1994b, Jameson et al., 1994; S. 
Hedrick, personal communication; K. A. Hogquist, S. C. J. 
and M. J. B., unpublished data). Although the basis under- 
lying this difference is unclear, these data imply that the 
assay system could confuse interpretation. The capacity 
of an antagonist ligand to inhibit positive selection in thy- 
mic organ culture is harder to explain. This may indicate 
genuine heterogeneity among TCR antagonists, or that 
TCR antagonists play a role in positive selection for CD8’ 
T cells but not CD4’ T cells. The situation may clarify as 
better models for studying the peptide requirements for 
positive selection of CD4+ T cells are developed. 
It is also not clear whether TCR antagonists are neces- 
sary or sufficient to induce normal positive selection. A 
critical experiment is to determine whether and where nat- 
ural antagonist ligands are expressed in vivo and what 
effect their expression has on T cell development (see 
below). 
The Possible Effects of Natural TCR Antagonlsts 
and Agonists 
While the existence or impact of TCR antagonists and 
partial agonists in vivo is unclear, it is interesting to specu- 
late brieflyon their possible roles. Thus, if TCR antagonists 
were responsible for driving positive selection, what effect 
would their expression have on mature T cells? If constitu- 
tively overexpressed, relative to an agonist ligand, we 
would expect to block all immune responses, not a very 
useful system! On the other hand, inducible expression 
of antagonist self-ligands might allow efficient control of 
immune responses; for example, up-regulation of MHC 
expression, by increasing the representation of MHC- 
associated self-peptides, might change the agonist/antag- 
onist balance in an immune response, and serve to regu- 
late it. Furthermore, partial agonists and antagonists could 
play a role in survival of naive or memory T cells. Data 
now exists that memory and naive T cells may have a fairly 
long lifespan in the absence of antigen (Hou et al., 1994; 
Lau et al., 1994; Sprent and Tough, 1994). Whether this 
prolonged survival occurs by default or requiressome form 
of interaction with self-MHC is still debatable (Hou et al., 
1994; Sprent and Tough, 1994). However, it is also possi- 
ble that resting T cells (naive, memory, or both) are main- 
tained in the periphery by constant engagement of weak 
TCR ligands, peptide-MHC complexes sufficient to gener- 
ate a minimal survival signal in the T cells. An attractive 
candidate for this “background noise” of TCR ligands are 
antagonists and partial agonists, since they would engage 
the TCR without provoking overt reactivity. 
New data indicate that T cells can mature and survive 
in the continuous presence of TCR antagonists. The Allen 
group (P. Allen, personal communication) created a TCR 
transgenic system whereby a variety of endogenous TCR 
a chains pair with a transgenic 8 chain to create reactivity 
to an allelic variant of mouse hemoglobin presented by 
class II MHC. Surprisingly, many of theseTcellsare antag- 
onized by the self-hemoglobin peptide-self-MHC com- 
plex. Thus, despite the fact that this peptide-MHC combi- 
nation is presented on APCs throughout the mouse 
(including the thymus), T cells develop, survive in the pe- 
riphery, and can be induced to respond. Although the con- 
centrations at which the self-hemoglobin-MHC acts as an 
antagonist in vitro are probably higher than those pre- 
sented in vivo, these authors present evidence that ubiqui- 
tous expression of this ligand does affect the resultant T 
cell population, increasing the coreceptor dependency of 
mature T cells (P. Allen, personal communication). This 
latter point is reminiscent of earlier data demonstrating 
that thymocytes bearing class I MHC-restricted TCRs 
adapt to the presence of an agonist/antagonist during thy- 
mic development by down-regulating surface expression 
of the coreceptor CD8 (Jameson et al., 1994). 
Conclusions 
Relatively little is known about the properties of TCR an- 
tagonists and partial agonists. However, the mere exis- 
tence of these ligands presents a challenge to models that 
portray the TCR as a simple on/off switch for activation. 
They also represent novel tools to study T cell develop- 
ment, stimulation, and regulation. Evidently, the phenom- 
enon is here to stay, but whether TCR antagonism and 
partial agonism persist as tricks for manipulating the T 
cell response, or become an important principle of normal 
T cell control, will require studying more physiological cir- 
cumstances. The ongoing search for natural TCR antago- 
nists and assessment of their impact on T cell differentia- 
tion and activity in vivo will be the first step in these new 
experiments. 
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